Holen Sie sich die Stockscreener-App
3.08
4.35%
-0.14
Handel nachbörslich:
3.09
0.010
+0.32%
Schlusskurs vom Vortag:
$3.22
Offen:
$3.21
24-Stunden-Volumen:
43,070
Relative Volume:
0.79
Marktkapitalisierung:
$25.85M
Einnahmen:
$442.00K
Nettoeinkommen (Verlust:
$-30.46M
KGV:
-0.6906
EPS:
-4.46
Netto-Cashflow:
$-27.47M
1W Leistung:
-21.43%
1M Leistung:
-31.56%
6M Leistung:
-32.90%
1J Leistung:
-63.80%
1-Tages-Spanne:
$2.9502
$3.21
1-Wochen-Bereich:
$2.9502
$3.91
52-Wochen-Spanne:
$2.9502
$9.20
Clene Inc Stock (CLNN) Company Profile
Firmenname
Clene Inc
Sektor
Branche
Telefon
801-676-9695
Adresse
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Vergleichen Sie CLNN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
3.08 | 25.85M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
30.43 | 37.02B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
59.79 | 32.67B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.49 | 28.11B | 12.75B | 1.34B | 1.13B | 3.87 |
|
MKC
Mccormick Co Inc
|
82.31 | 21.89B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
30.94 | 16.67B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-28 | Eingeleitet | Oppenheimer | Outperform |
Clene Inc Aktie (CLNN) Neueste Nachrichten
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Roth Capital Has Negative Estimate for Clene Q1 Earnings - Defense World
Clene Inc. settles debt with equity issuance - Investing.com
Clene Inc.'S (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available For On-Demand Viewing - MENAFN.COM
Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings - Defense World
Research Analysts Issue Forecasts for Clene Q1 Earnings - Defense World
What is HC Wainwright’s Estimate for Clene FY2028 Earnings? - Defense World
Clene stock touches 52-week low at $3.8 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $31 target on Clene stock post-results By Investing.com - Investing.com Canada
Clene stock touches 52-week low at $3.8 amid market challenges - Investing.com
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 - StreetInsider.com
H.C. Wainwright maintains $31 target on Clene stock post-results - Investing.com
Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright - Defense World
Clene to Present at Jones Las Vegas Technology and Innovation Conference - citybuzz -
Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Clene Inc. Reports 2024 Financial Results and Strategic Plans - TipRanks
Clene Inc (CLNN) Reports Q4 EPS of -$5.67, Revenue of $0.36M, Mi - GuruFocus
Clene Inc. Files For Mixed Shelf Of Up To $160 MillionSEC Filing -March 24, 2025 at 04:51 pm EDT - MarketScreener
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data - The Globe and Mail
Clene Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - The Manila Times
Breakthrough: Clene's ALS Treatment Shows 11.9-Month Survival Benefit in Severe Cases - Stock Titan
BiomednewsbreaksClene Inc. (NASDAQ: CLNN) Unveils Progress On CNM-Au8(R), Eyes Potential Fast-Track FDA Approval - MENAFN.COM
Bullish Clene Insiders Loaded Up On US$583.4k Of Stock - Yahoo Finance
Clene Inc. shareholder general resonance sells $12,091 in stock By Investing.com - Investing.com Australia
Clene Inc. shareholder general resonance sells $12,091 in stock - Investing.com
Dually-Listed Aerospace Stock Finds Premarket Success Following Key Announcement - The Globe and Mail
D. Boral Capital Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
HC Wainwright Reaffirms “Buy” Rating for Clene (NASDAQ:CLNN) - Defense World
H.C. Wainwright maintains Clene stock Buy rating, $31 target - Investing.com India
H.C. Wainwright maintains Clene stock Buy rating, $31 target By Investing.com - Investing.com South Africa
Clene reports ALS treatment survival benefit in trial By Investing.com - Investing.com Australia
Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients - streetwisereports.com
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports CNM-Au8 Significantly Improves Survival in ALS Patients - Financial Content
Clene Inc. (NASDAQ: CLNN) to Present CNM-Au8(R) Updates at 37th Annual Roth Conference - Financial Content
Clene reports ALS treatment survival benefit in trial - Investing.com India
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment - The Manila Times
Breakthrough: New ALS Drug Extends Patient Survival by 198 Days in Major Clinical Study - StockTitan
Clene (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit - Barchart
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Participate in 37th Annual Roth Conference - Financial Content
Clene to Present at the 37TH Annual Roth Conference - The Manila Times
Clene Inc. to Participate in 37th Annual Roth Conference with Virtual Fireside Chat and Investor Meetings - Nasdaq
Can Clene's Neurodegenerative Disease Treatments Transform ALS and MS Care? - StockTitan
Investornewsbreaks Clene Inc. (NASDAQ: CLNN) To Participate In 37Th Annual Roth Conference - MENAFN.COM
Clene (CLNN) to Release Quarterly Earnings on Wednesday - Defense World
Silicon Valley - Financial Content
Clene (NASDAQ: CLNN) CEO and CFO to Present at Investor Summit Virtual on March 11 - The Globe and Mail
New analyses in ALS planned to aid CNM-Au8’s accelerated approval - ALS News Today
What Will Clene Executives Reveal at the Upcoming Investor Summit? - StockTitan
Clene (NASDAQ:CLNN) Earns “Buy” Rating from HC Wainwright - Defense World
Finanzdaten der Clene Inc-Aktie (CLNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):